[go: up one dir, main page]

Radosevich, 2003 - Google Patents

Herpes virus ICP47 and US11 suppression of CTL activity adapted for use in gene therapy

Radosevich, 2003

Document ID
576663687694490095
Author
Radosevich T
Publication year

External Links

Snippet

A major stumbling block encountered in gene therapy clinical trials has been the rapid destruction of the therapeutic product by the host's immune response. The goal of this work is to diminish the host Cytotoxic T Lymphocyte (CTL) response to gene therapy transgenes …
Continue reading at search.proquest.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Similar Documents

Publication Publication Date Title
Yilmaz et al. Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy
Gschweng et al. Hematopoietic stem cells for cancer immunotherapy
US9144603B2 (en) Cell capable of expressing exogenous GITR ligand
AU2021203481A1 (en) Chimeric antigen receptors (CARs), compositions and methods of use thereof
US11530386B2 (en) Cells expressing recombinant growth factor receptors
US6149906A (en) Antigen presenting cells of the adipocyte lineage
KR102186180B1 (en) Cells responsible for immunity and expression vectors expressing immune function control factors
JP2018188475A (en) Methods for inducing partial apoptosis using caspase polypeptides
BR112020018620A2 (en) GENE REGULATION COMPOSITIONS AND METHODS FOR IMPROVED IMMUNOTHERAPY
CA2422597A1 (en) T cell receptor transfer into a candidate effector cell or a precursor thereof
US20060121030A1 (en) Use of cd 137 antagonists for the treatment of tumors
CN114127287A (en) Compositions and methods of acetylcholine receptor chimeric autoantibody receptor cells
AU712415B2 (en) Transplantation of genetically modified cells having low levels of class I MHC proteins on the cell surface
US8444965B2 (en) Tumor cells from immune privileged sites as base cells for cell-based cancer vaccines
Radosevich Herpes virus ICP47 and US11 suppression of CTL activity adapted for use in gene therapy
US7064111B1 (en) Use of soluble costimulatory factor for tumor immuno-gene therapy
Radosevich et al. Effective suppression of class I major histocompatibility complex expression by the US11 or ICP47 genes can be limited by cell type or interferon-γ exposure
EP0904786B1 (en) Tumor vaccination by use of autologous or HLA-related antigen presenting cell (APC) transduced with a tumour antigen and a foreign antigen capable of causing an immune reaction
Ghose et al. Immunogenicity of whole-cell tumor preparations infected with the ALVAC viral vector
Iwakami et al. Replication‐deficient adenovirus‐mediated transfer of B7‐1 (CD80) cDNA induces anti‐tumour immunity in isolated human lung cancer
Salman Investigation of the activation of tumour-specific immune responses by gene therapy strategies using a model tumour antigen
Blumenthal Gene therapy for the prevention and treatment of leukemia
HK40065151A (en) Chimeric antigen receptor-modified cells for the treatment of cldn6-expressing cancers
Gordon Investigation of potential problems associated with gene therapy
HESLOP et al. 19 Adoptive Cellular Immunotherapy